Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Receivables - Net: 2024-2025

Historic Receivables - Net for ARS Pharmaceuticals (SPRY) over the last 1 years, with Sep 2025 value amounting to $36.5 million.

  • ARS Pharmaceuticals' Receivables - Net rose 4615.52% to $36.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.5 million, marking a year-over-year increase of 4615.52%. This contributed to the annual value of $8.2 million for FY2024, which is N/A change from last year.
  • As of Q3 2025, ARS Pharmaceuticals' Receivables - Net stood at $36.5 million, which was up 45.07% from $25.1 million recorded in Q2 2025.
  • Over the past 5 years, ARS Pharmaceuticals' Receivables - Net peaked at $36.5 million during Q3 2025, and registered a low of $773,000 during Q3 2024.
  • In the last 2 years, ARS Pharmaceuticals' Receivables - Net had a median value of $9.3 million in 2025 and averaged $16.0 million.
  • Data for ARS Pharmaceuticals' Receivables - Net shows a peak YoY soared of 4,615.52% (in 2025) over the last 5 years.
  • ARS Pharmaceuticals' Receivables - Net (Quarterly) stood at $8.2 million in 2024, then spiked by 4,615.52% to $36.5 million in 2025.
  • Its Receivables - Net was $36.5 million in Q3 2025, compared to $25.1 million in Q2 2025 and $9.3 million in Q1 2025.